The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
Completed
Hebrew SeniorLife
Phase 2
2008-01-01
The purpose of this study is to examine the effects of blood pressure medications on
cognition and blood flow in hypertensive elderly patients with cognitive impairment. The
hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an
angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of
further cognitive decline, improved cerebral blood flow and its regulation, and preserved
physical function as compared to treatment with a diuretic (HCTZ), independent of blood
pressure level.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
